Thanks @Quiltman, that's interesting reading. I noticed that they seem to think it works in a sub group's of patients who hadn't previously taken Relyvrio. Another nail in the coffin for Amylyx' drug. I wonder what SLS-005's phase 1 results looked like and how many patients they had to gain ODD from the FDA?
It highlights how a phase 2/3 can uncover unknown issues when a greater number of patients with different histories are trialed. I wonder if any of our phase1 patients had ever been on Relyvrio?
Thanks @Quiltman, that's interesting reading. I noticed that...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $94.80M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.5¢ | $140.9K | 586.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12010 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 70000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
-0.010 ( 4.08 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.5¢ | 23.5¢ | 164909 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PAA (ASX) Chart |